BBatea Oncology
Batea Oncology is a Santiago de Compostela-based biotech spun out of the University Hospital and Health Research Institute of Santiago, founded in 2024 to develop new treatments for aggressive, low-survival cancers. Its lead asset, GlioHook, is a Class III implantable medical device placed during glioblastoma surgery that captures residual tumor cells and makes them more sensitive to radiotherapy, with a pilot clinical trial planned for 2026 across three Spanish hospitals.
SectorsBiotech, Oncology, Medical Devices, Healthcare
Start-up MapHealthtech & Bio › Medical devices & surgical hardware
Founders
J
Jorge Barbazán
Co-founder & CSO
Global models 5
MMonteris Medical
United States · www.monteris.com ↗
Develops an implantable laser-ablation device (NeuroBlate) for treating otherwise inoperable brain tumors including glioblastoma, matching Batea's model of a localized surgical device for brain cancer.
$275MComparable
AAlpheus Medical
United States · alpheusmedical.com ↗
Develops an ultrasound-activated sonodynamic therapy device specifically for newly diagnosed glioblastoma, targeting the same disease and device-based treatment approach as GlioHook.
$83.4MComparable
CCarThera
France · carthera.eu ↗
Develops SonoCloud, an ultrasound-emitting implant placed during glioblastoma surgery to enhance drug delivery to the tumor site, closely mirroring GlioHook's implanted-device-at-surgery model.
$58MComparable
DDNAtrix
United States · www.dnatrix.com ↗
Clinical-stage biotech developing an oncolytic virus therapy (DNX-2401) specifically for recurrent glioblastoma, matching Batea's disease focus though via a different treatment modality.
$43MComparable
NNovocure
Switzerland · www.novocure.com ↗
Commercializes Optune, a wearable tumor-treating-fields device for glioblastoma that, like GlioHook, targets residual/infiltrative tumor cells post-surgery to improve radiotherapy/treatment outcomes.
$10MComparable
In the same niche 72 others
See all in the Start-ups Map →
AAnaconda Biomed
Sant Cugat del Vallès
Series C (estimated) · €90.1M
IINBRAIN Neuroelectronics
Barcelona
Series B (estimated) · €84.5M
OOverture Life
Madrid
Venture Debt · €71.2M
M
Medlumics
Madrid
No stage disclosed · €57.8M
AAortyx
Barcelona
Series A · €16.9M
NNuubo
Madrid
Series B (estimated) · €16.3M
Notes: Most funded first
Investors 4
Open as list →
Funding rounds 1
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-18 | Seed | €750K |
Lead not disclosed
+3 more
|
News 6
Open as list →| Published | Article |
|---|---|
| 2026-06-02 |
Enisa and CaixaBank Honor the Best Startups at the EmprendeXXI Awards Grand Final ↗
Capital-Riesgo.es
2026-06-02 |
| 2025-12-15 |
La gallega Batea Oncology cierra una financiación total de 2,5 millones ↗
El Correo Gallego
2025-12-15 |
| 2025-09-19 |
Unirisco and Xesgalicia invest in Batea Oncology ↗
Biotech Spain
2025-09-19 |
| 2025-05-09 |
Rubén Ferreiro, Telmo Pérez, Batea Oncology y Marosa ganan los premios de emprendimiento de The Way Startup Summit ↗
El Referente
2025-05-09 |
| 2024-09-24 |
Batea Oncology selected in the IMPACTO program from the Asociación Española Contra el Cáncer, AECC ↗
AseBio
2024-09-24 |
| 2024-09-17 |
Batea Oncology, technology that traps tumour cells ↗
Bioga
2024-09-17 |